Publications by authors named "J F Bruxelle"
Article Synopsis
- C. difficile infection (CDI) is a significant public health issue, causing high rates of recurrence and economic burden, necessitating new treatments beyond traditional antibiotics.
- Various therapeutic strategies are being explored to prevent and treat CDI, including fecal transplantation and approaches that stimulate the immune system against the bacteria and its toxins.
- The document discusses both passive and active immunization methods, examining different targets, administration routes, and the results from animal models and human clinical trials.
Oligomannose-type glycans on the spike protein of HIV-1 constitute relevant epitopes to elicit broadly neutralizing antibodies (bnAbs). Herein we describe an improved synthesis of α- and β-linked hepta- and nonamannosyl ligands that were subsequently converted into BSA and CRM neoglycoconjugates. We assembled the ligands from anomeric 3-azidopropyl spacer glycosides from select 3-O-protected thiocresyl mannoside donors.
View Article and Find Full Text PDFThe occurrence of oligomannose-specific broadly neutralizing antibodies (bnAbs) has spurred efforts to develop immunogens that can elicit similar antibodies. Here, we report on the antigenicity and immunogenicity of a CRM-conjugate of a previously reported oligomannose mimetic. Oligomannose-specific bnAbs that are less dependent on interactions with the HIV envelope protein sequence showed strong binding to the glycoconjugates, with affinities approximating those reported for their cognate epitope.
View Article and Find Full Text PDFHuman Immunodeficiency Virus type-1 (HIV-1) establishes a latent viral reservoir soon after infection, which poses a major challenge for drug treatment and curative strategies. Many efforts are therefore focused on blocking infection. To this end, both viral and host factors relevant to the onset of infection need to be considered.
View Article and Find Full Text PDFArticle Synopsis
- Oligomannose-type glycans on HIV-1 gp120 are crucial for the effectiveness of broadly neutralizing antibodies (bnAbs), highlighting their significance in vaccine development.
- Attempts to create oligomannose-specific bnAbs through immunization with oligomannosidic glycoconjugates have had limited success, often attributed to B cell tolerance.
- Recent findings suggest that the trimming of oligomannosides by serum mannosidases in the body may further impede the development of antibodies capable of targeting the full-sized oligomannose, prompting the need for new immunization approaches or synthetic glycosides that resist this trimming.